Pancreatic Neoplasia

Pancreatic neoplasia encompasses a diverse group of benign and malignant tumors arising from the exocrine and endocrine components of the pancreas. In dogs and cats, the most common pancreatic tumors are pancreatic adenocarcinoma (exocrine) and insulinoma (endocrine, beta-cell origin). Other less common tumors include pancreatic ductal adenocarcinoma, acinar cell carcinoma, pancreatic adenoma, gastrinoma, glucagonoma, somatostatinoma, pancreatic lymphoma, and metastatic lesions. These neoplasms can cause significant morbidity due to local invasion, metastasis, and paraneoplastic syndromes. Surgical management is often the primary treatment for localized disease, but the prognosis varies widely depending on tumor type, stage, and resectability. The pancreas is a bilobed organ located in the cranial abdomen, with the right lobe in the mesoduodenum and the left lobe in the greater omentum. Surgical approaches include partial pancreatectomy, pancreaticoduodenectomy (rarely performed in veterinary patients), and debulking procedures. Accurate preoperative staging and careful patient selection are critical for successful surgical outcomes.

The exact etiology of pancreatic neoplasia in dogs and cats is largely unknown, but several factors have been implicated. Chronic pancreatitis has been suggested as a risk factor for pancreatic adenocarcinoma, although the causal relationship remains debated. Genetic mutations, such as activation of oncogenes (e.g., K-ras) and inactivation of tumor suppressor genes (e.g., p53), have been identified in human pancreatic cancer and may play a role in veterinary cases. Environmental factors, including exposure to certain carcinogens, have not been definitively linked. Insulinomas arise from beta cells and are often associated with multiple endocrine neoplasia (MEN) syndromes in humans, but such syndromes are rare in dogs and cats. Breed predispositions suggest a genetic component, with Boxers, Standard Poodles, and Golden Retrievers being overrepresented for insulinomas, while certain breeds like Airedale Terriers and German Shepherds may have a higher risk for pancreatic adenocarcinoma. Chronic inflammation, obesity, and diabetes mellitus have been proposed as risk factors, but evidence is limited. Iatrogenic causes are not recognized. The molecular pathogenesis involves dysregulation of cell growth, apoptosis, and angiogenesis, leading to uncontrolled proliferation and metastatic potential.

Pancreatic neoplasia is relatively uncommon in dogs and cats compared to other gastrointestinal tumors. Pancreatic adenocarcinoma accounts for approximately 1-2% of all canine tumors and 0.5-1% of feline tumors. It is more common in older animals, with a mean age of 10-12 years in dogs and 12-14 years in cats. No strong sex predilection is reported, though some studies suggest a slight male predominance in dogs. Certain breeds, such as Airedale Terriers, German Shepherds, and Golden Retrievers, may be at higher risk for pancreatic adenocarcinoma. Insulinomas are the most common endocrine tumor of the pancreas in dogs, with a mean age of 9-10 years, and are rare in cats. Breeds predisposed to insulinomas include Boxers, Standard Poodles, Golden Retrievers, and Labrador Retrievers. Pancreatic adenomas are rare and often incidental findings. Metastatic disease to the pancreas is uncommon but can occur with lymphoma, melanoma, and mammary carcinoma. The incidence of pancreatic neoplasia appears to be increasing, possibly due to improved diagnostic imaging and increased longevity of pets.

The pathophysiology of pancreatic neoplasia varies by tumor type. Exocrine pancreatic adenocarcinoma arises from ductal or acinar cells and is characterized by aggressive local invasion into surrounding tissues, including the duodenum, stomach, and major blood vessels. It frequently metastasizes to the regional lymph nodes, liver, and lungs. The tumor induces a dense desmoplastic reaction, which contributes to its firm consistency and difficulty in surgical resection. Malignant cells can obstruct the pancreatic duct, leading to secondary pancreatitis and exocrine pancreatic insufficiency. Endocrine tumors, such as insulinomas, arise from beta cells and secrete excessive insulin, causing hypoglycemia. The resulting neuroglycopenia leads to clinical signs such as weakness, collapse, seizures, and ataxia. Insulinomas are often small and may be difficult to locate intraoperatively. They can metastasize to the liver and regional lymph nodes. Gastrinomas secrete gastrin, leading to gastric hyperacidity and peptic ulceration. Glucagonomas cause hyperglycemia and a characteristic dermatopathy. The systemic effects of pancreatic neoplasia include cachexia, paraneoplastic syndromes, and coagulopathies. Surgical resection aims to remove the tumor burden, but the aggressive biology of exocrine tumors often limits curative outcomes.

Predisposing factors for pancreatic neoplasia include age (older animals), breed (as mentioned), and possibly chronic pancreatitis. Obesity and high-fat diets have been suggested as risk factors for pancreatic adenocarcinoma in humans, but evidence in dogs and cats is lacking. Genetic predisposition is likely, given breed associations. For insulinomas, no specific predisposing factors are identified, but the condition is more common in middle-aged to older dogs. There is no known sex predilection. Prior abdominal surgery or trauma is not a recognized risk factor. Environmental factors, such as exposure to pesticides or tobacco smoke, have not been studied in veterinary patients. The presence of other endocrine tumors (e.g., pheochromocytoma) may increase the risk of insulinoma, suggesting a possible MEN-like syndrome in dogs. Overall, the most significant predisposing factor is age, with the majority of cases occurring in senior pets.

Clinical signs of pancreatic neoplasia are often nonspecific and may be insidious in onset. In exocrine pancreatic adenocarcinoma, common signs include anorexia, weight loss, vomiting, diarrhea, and abdominal pain. Icterus may occur if the tumor obstructs the common bile duct. Some animals may present with acute pancreatitis-like signs. On physical examination, a cranial abdominal mass may be palpable in some cases, but this is often difficult due to the retroperitoneal location of the pancreas. Ascites may be present if there is peritoneal carcinomatosis. Insulinomas present with signs of hypoglycemia, including weakness, lethargy, tremors, ataxia, collapse, and seizures. These signs are often episodic and may be precipitated by fasting, exercise, or excitement. Physical examination is often unremarkable between episodes. Gastrinomas cause vomiting, diarrhea, and weight loss due to gastric ulceration. Glucagonomas cause hyperglycemia and a characteristic skin rash (necrolytic migratory erythema). In cats, pancreatic adenocarcinoma may present with vomiting, anorexia, and weight loss, and may be associated with concurrent pancreatitis or inflammatory bowel disease. Paraneoplastic alopecia has been reported in cats with pancreatic adenocarcinoma.

Differential diagnoses for pancreatic neoplasia include: 1) Chronic pancreatitis: presents with similar clinical signs (vomiting, abdominal pain) but is often associated with elevated serum lipase and amylase, and imaging may show a diffusely enlarged pancreas with peripancreatic fat stranding. 2) Pancreatic abscess or pseudocyst: may cause a palpable mass and systemic signs, but imaging and cytology can differentiate. 3) Hepatic neoplasia: can cause similar nonspecific signs and abdominal mass, but liver enzymes and imaging (ultrasound, CT) can help. 4) Gastrointestinal foreign body or obstruction: may cause vomiting and abdominal pain, but imaging shows a mechanical obstruction. 5) Mesenteric lymphadenopathy or lymphoma: can present with a cranial abdominal mass and weight loss; cytology or biopsy is needed. 6) Biliary tract disease (cholecystitis, bile duct obstruction): may cause icterus and vomiting; imaging and liver enzymes are helpful. 7) Peritonitis: can cause abdominal pain and effusion; abdominocentesis and cytology are diagnostic. 8) Adrenal gland tumors (pheochromocytoma): may cause similar clinical signs and a cranial abdominal mass; endocrine testing and imaging can differentiate. 9) Exocrine pancreatic insufficiency (EPI): causes weight loss and diarrhea but is not associated with a mass. 10) In cats, gastrointestinal lymphoma can mimic pancreatic neoplasia; histopathology is required for definitive diagnosis.

The diagnostic algorithm for pancreatic neoplasia begins with a thorough history and physical examination, with particular attention to the cranial abdomen. Baseline blood work, including a complete blood count, serum biochemistry profile, and urinalysis, is essential. Serum amylase and lipase may be elevated in pancreatitis but are not specific for neoplasia. For suspected insulinoma, a fasting blood glucose level and serum insulin concentration are measured; a low glucose with a normal or high insulin level is diagnostic. A ratio of insulin to glucose can be calculated. For other pancreatic tumors, abdominal ultrasound is the first-line imaging modality. Ultrasound can identify a pancreatic mass, assess the liver and lymph nodes for metastasis, and guide fine-needle aspiration (FNA) or biopsy. Computed tomography (CT) is superior for staging and surgical planning, providing detailed information about the tumor's extent, vascular invasion, and metastasis. Magnetic resonance imaging (MRI) may be used for further characterization. If a mass is identified, FNA with cytology can be performed, but a definitive diagnosis often requires histopathology from a surgical biopsy. Exploratory laparotomy may be necessary for diagnosis and treatment. In cases of insulinoma, intraoperative ultrasonography can help localize the tumor. Preoperative staging should include thoracic radiographs to rule out pulmonary metastasis.

Laboratory findings in pancreatic neoplasia are variable. In exocrine pancreatic adenocarcinoma, hematology may show a mild anemia of chronic disease or neutrophilia. Biochemistry may reveal elevated liver enzymes (ALT, ALP) if there is biliary obstruction or hepatic metastasis. Hyperbilirubinemia may be present. Serum amylase and lipase may be normal or elevated. Hypoalbuminemia may occur due to chronic inflammation or malnutrition. In insulinoma, the hallmark finding is hypoglycemia (glucose < 60 mg/dL) with concurrent elevated serum insulin levels. The amended insulin-to-glucose ratio (AIGR) can be calculated: AIGR = (serum insulin [µU/mL] × 100) / (serum glucose [mg/dL] - 30). An AIGR > 30 is suggestive of insulinoma. In gastrinoma, serum gastrin levels are elevated. Coagulation parameters (PT, aPTT) may be abnormal in cases of liver metastasis or disseminated intravascular coagulation. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated. Urinalysis may show glucosuria in cases of hyperglycemia. For surgical candidates, a complete coagulation panel and blood type are recommended.

Imaging plays a crucial role in the diagnosis and staging of pancreatic neoplasia. Abdominal radiography may reveal a soft tissue mass in the cranial abdomen, loss of serosal detail, or displacement of adjacent organs, but it is insensitive. Abdominal ultrasound is the most commonly used modality. It can identify a pancreatic mass, which may appear as a hypoechoic or mixed echogenic nodule. Ultrasound can also detect hepatic metastasis, lymphadenopathy, and biliary obstruction. Doppler ultrasound can assess vascular invasion. However, ultrasound has limitations in detecting small tumors, especially insulinomas. Computed tomography (CT) is the preferred advanced imaging technique for surgical planning. CT with contrast enhancement can delineate the tumor's size, location, and relationship to major vessels (e.g., portal vein, celiac artery). It can also identify metastasis to the liver, lymph nodes, and lungs. CT angiography is particularly useful for assessing vascular invasion. Magnetic resonance imaging (MRI) provides excellent soft tissue contrast and may be useful for characterizing pancreatic masses, but it is less commonly used due to cost and availability. Endoscopic ultrasound is not widely available in veterinary medicine. Intraoperative ultrasonography is valuable for localizing insulinomas that are not visible or palpable. Thoracic radiographs are essential to rule out pulmonary metastasis.

Cytology from fine-needle aspiration (FNA) of pancreatic masses can be diagnostic in some cases. Exocrine pancreatic adenocarcinoma may show clusters of epithelial cells with marked anisocytosis, anisokaryosis, and prominent nucleoli. Acinar cell carcinoma may have cells with zymogen granules. Endocrine tumors, such as insulinomas, have a characteristic appearance with uniform cells containing round nuclei and granular cytoplasm. However, cytology may be nondiagnostic due to the desmoplastic reaction or necrosis. Histopathology is the gold standard for diagnosis. Surgical biopsy or core needle biopsy provides tissue for histologic evaluation. Pancreatic adenocarcinoma is characterized by infiltrative glands or ducts surrounded by a dense fibrous stroma. Immunohistochemistry (IHC) can be used to differentiate tumor types; for example, chromogranin A and synaptophysin are positive in endocrine tumors. Ki-67 proliferation index may provide prognostic information. Surgical margins should be evaluated for tumor-free status. In cases of insulinoma, the tumor is often well-circumscribed but may have capsular invasion. Metastasis to regional lymph nodes and liver should be assessed.

Treatment of pancreatic neoplasia is primarily surgical, with the goal of complete resection. For exocrine pancreatic adenocarcinoma, partial pancreatectomy (distal pancreatectomy for left lobe tumors) or pancreaticoduodenectomy (for right lobe tumors involving the duodenum) may be performed. However, due to the aggressive nature and late presentation, many tumors are nonresectable. In such cases, debulking or palliative procedures (e.g., biliary diversion) may be considered. For insulinomas, surgical excision is the treatment of choice. The tumor is localized using palpation and intraoperative ultrasonography. A partial pancreatectomy is performed to remove the tumor with a margin of normal tissue. If the tumor is in the left lobe, a distal pancreatectomy is performed. If in the right lobe, a more extensive resection may be needed. Care must be taken to avoid damage to the pancreatic duct and major vessels. Postoperative complications include pancreatitis, which can be life-threatening. Medical management of insulinoma includes dietary changes (frequent small meals) and medications such as diazoxide or prednisone to manage hypoglycemia. For nonresectable tumors, chemotherapy (e.g., streptozocin) may be used, but efficacy is limited. For gastrinomas, surgical excision is attempted, and medical therapy with proton pump inhibitors (e.g., omeprazole) is used to control gastric hyperacidity. Supportive care, including fluid therapy, antiemetics, and nutritional support, is essential. In cats, pancreatic adenocarcinoma is often metastatic at diagnosis, and surgery is rarely curative.

The prognosis for pancreatic neoplasia is generally poor, especially for exocrine pancreatic adenocarcinoma. The median survival time for dogs with pancreatic adenocarcinoma is approximately 3-6 months, even with surgical resection. Factors associated with a worse prognosis include advanced stage, presence of metastasis, incomplete resection, and high histologic grade. Cats with pancreatic adenocarcinoma have a median survival of about 1-2 months. In contrast, insulinomas have a better prognosis if completely resected. Dogs with insulinoma that undergo successful surgical excision have a median survival of 12-18 months, with some living longer. Factors that negatively affect prognosis include metastasis at the time of surgery, high insulin levels, and incomplete resection. Recurrence of hypoglycemia is common. Gastrinomas have a guarded prognosis due to high metastatic potential. Overall, early detection and complete surgical resection offer the best chance for prolonged survival, but the aggressive biology of pancreatic tumors often limits outcomes.

Postoperative follow-up for pancreatic neoplasia is critical. After surgery, patients should be monitored closely for complications such as pancreatitis, which can occur within 24-72 hours. Serial measurements of serum amylase, lipase, and glucose are recommended. For insulinoma patients, blood glucose should be monitored frequently to ensure normoglycemia. Suture removal is typically 10-14 days after surgery. Abdominal ultrasound or CT should be repeated at 1, 3, and 6 months postoperatively to assess for recurrence or metastasis. For insulinoma, serial blood glucose and insulin levels are recommended every 3-6 months. For exocrine tumors, thoracic radiographs should be repeated every 3 months to detect pulmonary metastasis. Activity restriction is advised for 2-4 weeks postoperatively to allow healing. Nutritional support may be needed if exocrine pancreatic insufficiency develops. Long-term monitoring for paraneoplastic syndromes is important. The owner should be educated on signs of recurrence, such as weight loss, vomiting, or hypoglycemic episodes.

Clinical pearls: 1) Always perform a thorough abdominal exploration during surgery for pancreatic masses, as small insulinomas may be hidden within the parenchyma. 2) Use intraoperative ultrasonography to localize insulinomas that are not palpable. 3) When performing a partial pancreatectomy, ligate vessels carefully to avoid hemorrhage and preserve the pancreatic duct. 4) Consider a Jackson-Pratt drain if there is concern for pancreatic leakage. 5) In cases of insulinoma, avoid excessive manipulation of the tumor to prevent insulin release and hypoglycemia. 6) Preoperative administration of dextrose may be necessary to maintain euglycemia. Pitfalls: 1) Failure to recognize that pancreatic adenocarcinoma often has metastasized at the time of diagnosis, leading to unnecessary surgery. 2) Incomplete resection due to inadequate margins, leading to recurrence. 3) Postoperative pancreatitis is a common and potentially fatal complication; monitor closely and treat aggressively. 4) Overlooking concurrent diseases such as pancreatitis or inflammatory bowel disease. 5) In insulinoma, not checking blood glucose postoperatively can lead to undetected hyperglycemia or hypoglycemia. 6) Using electrocautery near the pancreatic duct can cause thermal injury and leakage.

Perioperative antimicrobial prophylaxis: Cefazolin (22 mg/kg IV) administered 30 minutes before incision and repeated every 90 minutes during surgery. Postoperative analgesia: Opioids such as hydromorphone (0.05-0.1 mg/kg IV q4-6h) or fentanyl CRI (2-5 µg/kg/h) for 24-48 hours. NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h) can be used after renal function is assessed, but caution in patients with hepatic or renal compromise. Local anesthesia: Bupivacaine (1-2 mg/kg) as an incisional line block or epidural. Antiemetics: Maropitant (1 mg/kg IV q24h) or ondansetron (0.1-0.2 mg/kg IV q8h). For insulinoma: Diazoxide (5-10 mg/kg PO q12h) to inhibit insulin release; prednisone (0.25-0.5 mg/kg PO q12h) to increase blood glucose. For gastrinoma: Omeprazole (0.7-1 mg/kg PO q12h) or pantoprazole (0.5-1 mg/kg IV q24h). For pancreatitis: Fluid therapy with balanced crystalloids, analgesia, and nutritional support. Octreotide (10-20 µg/kg SC q8h) may be used to reduce insulin secretion in insulinoma. Chemotherapy: Streptozocin (500 mg/m² IV every 3 weeks) with saline diuresis, but nephrotoxicity is a concern. Always adjust dosages for hepatic or renal impairment.

The veterinary literature on pancreatic neoplasia is limited to retrospective studies and case series. A study by Withrow et al. (2000) reported a median survival of 3 months for dogs with pancreatic adenocarcinoma treated with surgery alone. Another study by Tappin et al. (2008) found that dogs with insulinoma that underwent surgical excision had a median survival of 18 months, with a 1-year survival rate of 70%. A multicenter study by Polton et al. (2007) evaluated the use of streptozocin in dogs with insulinoma and reported a response rate of 50%, but with significant toxicity. For feline pancreatic adenocarcinoma, a study by Seaman et al. (2004) reported a median survival of 1 month. There are no prospective randomized controlled trials due to the rarity of the disease. Consensus guidelines from the ACVS and ECVS recommend surgical resection as the primary treatment for localized pancreatic tumors, with careful patient selection and staging. Recent advances in imaging, such as CT, have improved surgical planning. The use of intraoperative ultrasonography is recommended for insulinoma localization. Overall, the evidence supports surgical resection for insulinomas with a good prognosis, while exocrine tumors carry a poor prognosis regardless of treatment.